• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Adopting Model-Informed Precision-Dosing for Eculizumab in Transplant Associated-Thrombotic Microangiopathy to Gene Therapies.

作者信息

Jodele Sonata, Mizuno Kana, Sabulski Anthony, Vinks Alexander A

机构信息

Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

出版信息

Clin Pharmacol Ther. 2023 Sep;114(3):511-514. doi: 10.1002/cpt.2966. Epub 2023 Jun 30.

DOI:10.1002/cpt.2966
PMID:37387481
Abstract
摘要

相似文献

1
Adopting Model-Informed Precision-Dosing for Eculizumab in Transplant Associated-Thrombotic Microangiopathy to Gene Therapies.将依库珠单抗的模型指导精准给药应用于移植相关血栓性微血管病至基因疗法。
Clin Pharmacol Ther. 2023 Sep;114(3):511-514. doi: 10.1002/cpt.2966. Epub 2023 Jun 30.
2
Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy.依库珠单抗治疗异基因造血细胞移植相关血栓性微血管病的成人患者
Bone Marrow Transplant. 2016 Sep;51(9):1241-4. doi: 10.1038/bmt.2016.87. Epub 2016 Apr 11.
3
Eculizumab was safe and effective in the management of transplant-associated thrombotic microangiopathy in a heart transplant recipient with concurrent COVID-19 infection.依库珠单抗在一名合并新型冠状病毒肺炎感染的心脏移植受者的移植相关血栓性微血管病治疗中安全有效。
Intern Med J. 2023 Aug;53(8):1506-1508. doi: 10.1111/imj.16178.
4
A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab.1例抗磷脂抗体综合征相关血栓性微血管病经依库珠单抗治疗成功
Transplantation. 2014 Aug 15;98(3):e17-8. doi: 10.1097/TP.0000000000000267.
5
Thrombotic microangiopathy: eculizumab for atypical haemolytic uraemic syndrome: what next?血栓性微血管病：依库珠单抗治疗非典型溶血性尿毒症综合征：下一步何去何从？
Nat Rev Nephrol. 2013 Sep;9(9):495-6. doi: 10.1038/nrneph.2013.150. Epub 2013 Aug 6.
6
The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy.依库珠单抗在他克莫司诱导的血栓性微血管病中的应用。
J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620947266. doi: 10.1177/2324709620947266.
7
Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: A case report.依库珠单抗治疗药物性新发移植后血栓性微血管病：一例报告
Clin Nephrol. 2015 Feb;83(2):125-9. doi: 10.5414/CN108163.
8
Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.依库珠单抗清除率的可变性需要进行药效学监测，以优化造血干细胞移植后血栓性微血管病的治疗。
Biol Blood Marrow Transplant. 2016 Feb;22(2):307-315. doi: 10.1016/j.bbmt.2015.10.002. Epub 2015 Oct 9.
9
Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.依库珠单抗治疗儿童严重造血干细胞移植相关性血栓性微血管病。
Biol Blood Marrow Transplant. 2014 Apr;20(4):518-25. doi: 10.1016/j.bbmt.2013.12.565. Epub 2013 Dec 25.
10
[Clinical efficacy of eculizumab as treatment of gemcitabine-induced thrombotic microangiopathy: A case report].[依库珠单抗治疗吉西他滨诱导的血栓性微血管病的临床疗效：病例报告]
Rev Med Interne. 2016 Oct;37(10):701-704. doi: 10.1016/j.revmed.2015.12.027. Epub 2016 Jan 28.

引用本文的文献

1
Translating biomarker insights into practice: a path forward in TA-TMA management.将生物标志物见解转化为实践：TA-TMA 管理的前进之路。
Front Med (Lausanne). 2025 May 8;12:1550365. doi: 10.3389/fmed.2025.1550365. eCollection 2025.
2
The potential for therapeutic drug monitoring of belatacept and other biologicals in solid organ transplantation.实体器官移植中贝拉西普及其他生物制剂的治疗药物监测潜力。
Br J Clin Pharmacol. 2025 Jun;91(6):1542-1550. doi: 10.1111/bcp.16170. Epub 2024 Jul 26.